These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 26966281)

  • 21. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry).
    Spinler SA; Cziraky MJ; Willey VJ; Tang F; Maddox TM; Thomas T; Dueñas GG; Virani SS;
    Am J Cardiol; 2015 Aug; 116(4):547-53. PubMed ID: 26089010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity.
    Rohatgi A
    Prog Cardiovasc Dis; 2015; 58(1):32-40. PubMed ID: 25968932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-Density Lipoprotein Mimetics: a Therapeutic Tool for Atherosclerotic Diseases.
    Ikenaga M; Higaki Y; Saku K; Uehara Y
    J Atheroscler Thromb; 2016; 23(4):385-94. PubMed ID: 26830201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet.
    Shimizu T; Miura S; Tanigawa H; Kuwano T; Zhang B; Uehara Y; Saku K
    Arterioscler Thromb Vasc Biol; 2014 Oct; 34(10):2246-53. PubMed ID: 25104799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of dyslipidemia and cardiovascular outcomes: the journey so far--is this the end for statins?
    Zoungas S; Curtis AJ; McNeil JJ; Tonkin AM
    Clin Pharmacol Ther; 2014 Aug; 96(2):192-205. PubMed ID: 24727468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pitavastatin and HDL: Effects on plasma levels and function(s).
    Pirillo A; Catapano AL
    Atheroscler Suppl; 2017 Jul; 27():e1-e9. PubMed ID: 28716185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials.
    Taylor AJ
    Am J Cardiol; 2008 Apr; 101(8A):36B-43B. PubMed ID: 18375240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of HDL in those with diabetes.
    Santos-Gallego CG; Rosenson RS
    Curr Cardiol Rep; 2014 Aug; 16(8):512. PubMed ID: 24950673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HDL and Reverse Cholesterol Transport Biomarkers.
    Riggs KA; Rohatgi A
    Methodist Debakey Cardiovasc J; 2019; 15(1):39-46. PubMed ID: 31049148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials.
    Deedwania P; Singh V; Davidson MH
    Am J Cardiol; 2009 Nov; 104(10 Suppl):3E-9E. PubMed ID: 19895938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease.
    Sacks FM; Jensen MK
    Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):487-499. PubMed ID: 29371248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attainment of normal lipid levels among high cardiovascular risk patients: pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada.
    Ambegaonkar BM; Bash LD; Chirovsky DR; Jameson K; Grant S; Nocea G; Pettersson B; Sazonov V
    Eur J Intern Med; 2013 Oct; 24(7):656-63. PubMed ID: 23953848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current guidelines for high-density lipoprotein cholesterol in therapy and future directions.
    Subedi BH; Joshi PH; Jones SR; Martin SS; Blaha MJ; Michos ED
    Vasc Health Risk Manag; 2014; 10():205-16. PubMed ID: 24748800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting high-density lipoproteins: update on a promising therapy.
    Verdier C; Martinez LO; Ferrières J; Elbaz M; Genoux A; Perret B
    Arch Cardiovasc Dis; 2013 Nov; 106(11):601-11. PubMed ID: 24074699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment options for low high-density lipoproteins.
    Hafiane A; Kellett S; Genest J
    Curr Opin Endocrinol Diabetes Obes; 2014 Apr; 21(2):134-9. PubMed ID: 24535232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis.
    Riaz H; Khan SU; Rahman H; Shah NP; Kaluski E; Lincoff AM; Nissen SE
    Eur J Prev Cardiol; 2019 Mar; 26(5):533-543. PubMed ID: 30861690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression.
    Negi S; Ballantyne CM
    J Clin Lipidol; 2010; 4(5):365-70. PubMed ID: 21122680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.